{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:16:29Z","timestamp":1793038589522,"version":"4.5.0"},"reference-count":73,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/501100010018","name":"Doctoral Start-up Foundation of Liaoning Province","doi-asserted-by":"crossref","award":["20180540024"],"award-info":[{"award-number":["20180540024"]}],"id":[{"id":"10.13039\/501100010018","id-type":"DOI","asserted-by":"crossref"}]},{"name":"345 Talent Project of Shengjing Hospital of China Medical University","award":["M0397"],"award-info":[{"award-number":["M0397"]}]},{"name":"Organization Department of Liaoning Provincial Party committee","award":["XLYC1908031"],"award-info":[{"award-number":["XLYC1908031"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1080\/17425247.2021.1825376","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T05:19:36Z","timestamp":1600665576000},"page":"187-203","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":149,"title":["Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action"],"prefix":"10.1080","volume":"18","author":[{"given":"Yingyan","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0978-2363","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1039\/C8DT00838H"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1039\/C8DT90088D"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28832"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.01.011"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.01.007"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00182-w"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900734"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3141"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43656"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)33328-7"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3254-4"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2016.2152"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2019.05.007"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.08.005"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0235"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.06.016"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13521"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0581-9"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13281"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.06.002"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9016"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.020"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.045"},{"key":"cit0028","unstructured":"Combination Therapy With NC-6004 and pembrolizumab in head and neck cancer subjects who have failed platinum regimen [cited 2020 Feb 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03771820?term=NC6004&rank=1"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.262"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2016.161"},{"key":"cit0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2019.08.587","volume-title":"A P \u2161 study of toripalimab,a PD-1 mAb,in combination with chemotherapy in EGFR+ advanced NSCLC patients failed to prior EGFR TKI therapies","author":"Zhang J","year":"2019"},{"key":"cit0037","unstructured":"Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI[cited 2020 Mar 02]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924050?term=Toripalimab&cond=NSCLC&rank=2"},{"key":"cit0038","unstructured":"A study to evaluate the efficacy and safety of toripalimab or placebo combined with chemotherapy in treatment-naive advanced NSCLC [cited 2020 Mar 02]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03856411?term=Toripalimab&cond=NSCLC&rank=1"},{"key":"cit0039","unstructured":"Phase III study of comparing TORIPALIMAB INJECTION versus placebo combined with chemotherapy for recurrent or metastatic nasophapyngeal cancer [cited 2020 Mar 02]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03581786?term=NCT03581786&rank=1"},{"key":"cit0040","unstructured":"Toripalimab or placebo with paclitaxel and cisplatin in esophageal squamous cell carcinoma (JUPITER06) [cited 2020 Mar 02]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03829969?term=03829969&rank=1"},{"key":"cit0041","unstructured":"PD-1(Programmed Death-1) antibody +GP as first line treatment for Triple Negative Breast Cancer(TNBC) patients [cited 2020 Mar 02]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03251313?term=JS001&cond=TNBC+-+Triple-Negative+Breast+Cancer&rank=1"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tby005"},{"key":"cit0043","volume-title":"Phase \u2160b study of sintilimab in combination with chempotherapy for 1L advanced or metastatic Non-small Cell Lung Cancer (NSCLC)","author":"Xu N","year":"2019"},{"key":"cit0044","unstructured":"Efficacy and safety evaluation of sintilimab in patients with advanced or recurrent non-squamous NSCLC [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03607539?term=orient+11&draw=2&rank=1"},{"key":"cit0045","unstructured":"Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Recurrent Squamous NSCLC [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03629925?term=orient+12&draw=2&rank=1"},{"key":"cit0046","unstructured":"Study A. Comparing the efficacy and safety between IBI308 and docetaxel in patients with advanced or metastatic NSCLC [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150875?term=ORIENT-3&rank=1"},{"key":"cit0047","unstructured":"Sintilimab \u00b1 IBI305 plus chemotherapy (pemetrexed + cisplatin) for EGFRm + locally advanced or metastasis non-squamous NSCLC patients after EGFR-TKI treatment failure [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03802240?term=%28NCT03802240%29&draw=2&rank=1"},{"key":"cit0048","volume-title":"Efficacy and safety of sintilimab in combination with CapeOx in first-line gastric or Gastroesophageal Junction Carcinoma (GC\/GEJC)","author":"Xu N","year":"2019"},{"key":"cit0049","unstructured":"Efficacy and safety evaluation of sintilimab or placebo in combination with XELOX as first line treatment in patients with gastric cancer [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745170?term=%28NCT03745170%29&draw=2&rank=1"},{"key":"cit0050","unstructured":"Sintilimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (ORIENT-15) [cited 2020 Mar 06]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03748134?term=NCT03748134&draw=2&rank=1"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.425"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4074"},{"key":"cit0054","volume-title":"SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: results from a single-arm exploratory study","author":"Chen X","year":"2019"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9"},{"key":"cit0056","unstructured":"A study to evaluate the safety and efficacy of SHR-1210, gemcitabine and cis-platinum by R\/M NPC subjects [cited 2020 Mar 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03121716?term=NCT03121716&draw=2&rank=1"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4031"},{"key":"cit0058","unstructured":"A study to evaluate SHR-1210 in combination with capecitabine + oxaliplatin sequenced by SHR-1210 + apatinib as first-line therapy in treatment of advanced gastric cancer [cited 2020 Mar 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03813784?term=NCT03813784&draw=2&rank=1"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31855"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4033"},{"key":"cit0061","unstructured":"Study of SHR-1210 in combination with chemotherapy in advanced esophageal cancer [cited 2020 Mar 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03691090?term=%28NCT03691090%29&draw=2&rank=1"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0492-0"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0881"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.159"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.211722"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0037"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40269"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00707-4"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18542"},{"key":"cit0072","first-page":"OL1366","volume":"56","author":"Qin X","year":"2010","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.04.005"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2021.1825376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:32Z","timestamp":1620432032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2021.1825376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1080\/17425247.2021.1825376"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2021.1825376","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}